Canada’s regulator has issued marketing authorizations for Sandoz’s semaglutide, a GLP-1 receptor agonist injection and a generic version of Ozempic.
Canada’s regulator has issued marketing authorizations for Sandoz’s semaglutide, a GLP-1 receptor agonist injection and a generic version of Ozempic.